Kate Butler

Kate Butler is Chief Financial Officer of Syncona Investment Management Ltd.

Kate joined Syncona in 2022 as Group Finance Director, and was promoted to CFO in April 2024. She is a Director on the Board of Slingshot Therapeutics.

She is a senior finance leader with over 20 years' experience in finance across multiple roles in the life sciences sector. Kate joined Syncona from Awakn, a Canadian listed biotech start-up where she was CFO. Prior to that, she was Head of Finance for Kite Europe, where she worked on the launch of Yescarta, one of the first approved CAR-T therapies, and held senior finance roles at Gilead Sciences Inc. and Vectura plc.

Kate has FTSE 100 experience working with Anglo American plc and spent nine years at Ernst & Young LLP, where she qualified as a chartered accountant.

Syncona portfolio companies

• Slingshot Therapeutics (Director)